Welcome to our dedicated page for LeonaBio SEC filings (Ticker: ATHA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on LeonaBio's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into LeonaBio's regulatory disclosures and financial reporting.
Athira Pharma, Inc. (NASDAQ: ATHA) has filed a Form 144, disclosing a proposed sale of 25,123 common shares through Morgan Stanley Smith Barney LLC, Executive Financial Services, 1 New York Plaza, on or about 01 Jul 2025. These shares equal roughly 0.06 % of the company’s 39,042,445 shares outstanding.
The shares were acquired on 30 Jun 2025 via a “Restricted Stock Lapse” tied to equity compensation. No other sales by the same insider have occurred in the past three months according to the filing. Aggregate market value is listed as 7,374 (units not specified). The sale will be executed on the NASDAQ exchange.
Because the transaction size is immaterial compared with ATHA’s float and no identity or role of the seller is provided, the filing is generally viewed as routine rather than a signal of strategic or operational change. Form 144 merely gives notice of intent; the sale may or may not ultimately occur. Investors may interpret the filing as normal portfolio or tax management following the vesting of stock-based compensation, rather than a negative assessment of Athira Pharma’s prospects.
Athira Pharma, Inc. (ATHA) has filed a Form 144 indicating an insider’s intention to sell shares. The notice covers the proposed sale of 10,842 common shares through Morgan Stanley Smith Barney on or after 01 July 2025. The shares were originally acquired on 30 June 2025 via the lapse of restrictions on equity compensation, as disclosed in the filing’s “Nature of Acquisition Transaction.”
With 39,040,945 shares outstanding, the proposed sale represents only about 0.03 % of total shares, suggesting minimal dilution or market overhang. There were no other sales reported in the past three months by the same filer. The filing also certifies that the seller is unaware of any material, non-public adverse information about the company.
Form 144 filings are routine compliance documents required when affiliates intend to sell restricted or control stock. While they do not guarantee a sale will occur, they provide advance notice to the market. Because the volume is small relative to shares outstanding and there are no accompanying negative disclosures, the near-term impact on ATHA’s share price is likely limited. Nevertheless, investors often watch insider activity for sentiment signals; the timing—immediately after a restriction lapse—may be interpreted as profit-taking by the holder.
Athira Pharma, Inc. (ticker ATHA) has filed a Form 144, notifying the SEC of an intended insider sale of up to 8,526 common shares through broker Morgan Stanley Smith Barney LLC. The proposed sale is scheduled for 01 July 2025 on Nasdaq. The shares were recently acquired on 30 June 2025 via a restricted-stock lapse tied to equity compensation. With 39,042,445 total shares outstanding, the transaction represents roughly 0.02 % of the float, indicating minimal dilution or market impact. No prior sales were reported in the past three months, and the filer affirms no undisclosed adverse information. Overall, this appears to be a routine liquidity move rather than a signal of fundamental change.